TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00746772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Purslane 235mg/day in one dosage
Description: Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo : one dosage
Description: Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months .
Study: NCT04210713

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: 200 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: 200 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Matched placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Matched placebo
Study: NCT03115645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Work
Description: The intervention consists of the introduction of sit-stand workstations and desk bikes in the participants work environment in a ratio of 1:2 with traditional desks and chairs. Employees will receive a half hour intervention session at the start of the intervention from an occupational physiotherapist, who will provide further intervention support in the ensuing 12 weeks. Intervention participants will also receive an activity tracker which provides feedback on sitting time and physical activity levels.
Study: NCT03618225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Duloxetine 60mg
Description: duloxetine 60 mg orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo pill
Description: placebo pill orally 2 hours before the surgical procedure and at 24 hours after the surgical procedure
Study: NCT02887144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura
Description: SenSura is a Commercial and CE-marked ostomy product (1pc) manufactured by Coloplast A/S
Study: NCT05327777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Investigators provided set opioid prescriptions for 10 pills each patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zero Opioid Protocol
Description: Investigators provided no opioid prescriptions at discharge and instead provided information on non-narcotic pain control.
Study: NCT03881943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 60 mg
Description: Potent antiplatelet agent, 60mg twice daily for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100 MG Oral Tablet, Enteric Coated
Description: antiplatelet agent, 100mg once daily for 3 months
Study: NCT00151593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Celsior®
Description: Graft preservation solution
Study: NCT03276559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMPOWER
Description: EMPOWER is a manualized treatment delivered based in cognitive behavioral and acceptance and commitment therapies delivered by a trained mental health professional that utilizes breathing and grounding exercises, mindfulness meditation, psychoeducation, imaginal dialogue with the patient, and coping rehearsal techniques.~The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each module. It can either be administered in one session or many sessions to accommodate the dynamic nature of ICU, and has two booster follow-up calls (roughly 45 minutes each) in the month following initial treatment.
Study: NCT03276559

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMPOWER
Description: EMPOWER is a manualized treatment delivered based in cognitive behavioral and acceptance and commitment therapies delivered by a trained mental health professional that utilizes breathing and grounding exercises, mindfulness meditation, psychoeducation, imaginal dialogue with the patient, and coping rehearsal techniques.~The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each module. It can either be administered in one session or many sessions to accommodate the dynamic nature of ICU, and has two booster follow-up calls (roughly 45 minutes each) in the month following initial treatment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Usual Care
Description: Enhanced usual care consists of standard ICU psychosocial support for caregivers like social work, chaplaincy, or palliative care team visits as charted in the patient's medical record. Participants assigned to EUC will also receive a general information guide for caregivers as well as a site-specific list of caregiver resources.
Study: NCT00091377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IV 40 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: IV 80 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenoxodiol
Description: IV 3 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenoxodiol
Description: IV 3 mg/kg
Study: NCT04122950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: The participants in the Exergaming group will use the PlayPulse exergame for 45 minutes a minimum of three times per week for 8 weeks. Between 8 and 12 weeks the exergaming group will be provided with free access to the exergame but without the two mandatory exergaming sessions
Study: NCT00402103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: All patients received aliskiren 150 mg for the first two weeks; dose was then force-titrated to aliskiren 300 mg for 52 weeks duration
Study: NCT00773383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RG1507
Description: iv 9mg/kg weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150mg oral daily
Study: NCT00402103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: All patients received aliskiren 150 mg for the first two weeks; dose was then force-titrated to aliskiren 300 mg for 52 weeks duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: All patients received amlodipine 5 mg for the first two weeks; dose was then force-titrated to amlodipine 10 mg for 52 weeks duration
Study: NCT02935374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: The children with acute otitis media will be treated with amoxixillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-Potassium Clavulanate
Description: The children with acute otitis media will be treated with amoxixillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
Study: NCT02992431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory patient care planning
Description: Intervention includes the patient activation questionnaire form, a visit to the nurse who conducts the measurements (blood pressure, waist measurement, weight and length) and a visit to the general practitioner who discusses and agrees with the patient about the treatment goals and follow-up resulting in the written PPCP.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care including standard disease specific follow-up with visit to general practitioner.
Study: NCT02887144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura test product
Description: SenSura test product is a CE-marked ostomy product (1pc) manufactured by Coloplast A/S

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SenSura test product
Description: SenSura test product is a CE-marked ostomy product (1pc) manufactured by Coloplast A/S
Study: NCT01601015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Manual therapy of Suboccipital soft tissue Inhibition is performed with patient in supine position. The patient's head leans against the physiotherapist's hands, which palpate suboccipital muscles by sliding fingertips until contacting posterior arch of atlas. At this point, a deep and progressive gliding pressure is applied, for 10 minutes. The purpose of this technique is to release suboccipital muscle spasm, which can be responsible for the mobility dysfunction of the occiput-atlas-axis joint.
Study: NCT00402103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: All patients received amlodipine 5 mg for the first two weeks; dose was then force-titrated to amlodipine 10 mg for 52 weeks duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Optional addition of Hydrochlorothiazide (HCTZ)of 12.5 mg with increase to 25 mg was allowed for patients not adequately controlled.
Study: NCT01701323

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study: NCT02163447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Study: NCT01701323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study: NCT04801654

Intervention type: DIAGNOSTIC_TEST
Intervention: blood sample
Description: preoperative and at 6 months and 1 year follow-up after the surgery the patients will take a blood sample
Study: NCT01447147

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules once daily
Study: NCT02163447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy
Study: NCT01635582

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional hand exercise program
Description: Exercises targeted to improve finger range of motion and hand strength.The exercises will be performed 30 minutes,four times per week for six weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer gaming hand exercise regimen
Description: Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for six weeks
Study: NCT03595462

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snack
Description: Hummus and Pretzels- The study participants will be provided with a hummus and pretzels snack to consume every day for a week. The energy content of the hummus and pretzels will be \~240 kcal. The hummus and pretzels contain 6 g protein, 27 g carbohydrates, 0 g sugar, 4 g fiber, and 12 g fat.~Granola Bars- The study participants will be provided with two granola bars to consume every day for a week. The energy content of the two granola bars will be \~240 kcal. The two granola bars contain 4 g protein, 38 g carbohydrates, 16 g sugar, 2 g fiber, and 9 g fat.
Study: NCT01447147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX140-B
Description: CCX140-B capsules once daily (Group B)
Study: NCT01601015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
Study: NCT03595462

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Snack
Description: The study participants will not be provided with any snack and will be told to consume nothing from 2-4pm for a week.
Study: NCT01889407

Intervention type: DRUG
Intervention: Idarubicin
Description: 8 mg/m2, iv drip on days 1-3
Study: NCT04207528

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Writing
Description: After completing the baseline questionnaire, participants will be randomized to one of two conditions-a peer helping condition or a facts-only writing control. Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 5 minutes per session. Topics covered in each session will vary and are related to common themes relating to life as a first-year university student (e.g., academics, adjusting to university, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 day apart and take place all within the same week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing
Description: After completing the baseline questionnaire, participants will be randomized to one of two conditions-a peer helping condition or a facts-only writing control. Participants will receive general instructions for completing the writing sessions and will be asked to write for at least 5 minutes per session. Topics covered in each session will vary and are related to common themes relating to life as a first-year university student (e.g., academics, adjusting to university, etc.). Participants will be instructed not to worry about grammar, spelling, or sentence structure and reminded that their responses will remain anonymous. Writing sessions (four in total) will be spaced 1 day apart and take place all within the same week.
Study: NCT03519139

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individual dietary counselling
Description: individual dietary counsellings with the aim to ensure sufficient coverage of energy and protein needs of the test subjects
Study: NCT01637480

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbopelvic manipulation
Description: High-velocity-low-amplitude thrust manipulation of the lumbopelvic region

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbopelvic manipulation
Description: High-velocity-low-amplitude thrust manipulation of the lumbopelvic region
Study: NCT02025660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mw, 0.3ml x three days sc

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00694408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyl prednisolone, hydrocortisone, prednisolone
Description: Will be specific dependant on weight of patients

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No steroids
Description: Children undergoing primary liver transplant will receive monoclonal antibodies and tacrolimus as per protocol
Study: NCT01318369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namisol
Description: Single dose delta-9-tetrahydrocannabinol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
Study: NCT02975856

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Table Red Wine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Young Port Red Wine
Study: NCT05589753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxia
Description: The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 6 days. On the final 4 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
Study: NCT01447147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX140-B
Description: CCX140-B capsules once daily (Group C)
Study: NCT02296359

Intervention type: BIOLOGICAL
Intervention: Influenza Vaccination
Description: The individuals will be followed to observe their immune system activation, following their vaccination with the standard influenza vaccine approved for the year by the FDA.

Intervention type: BIOLOGICAL
Intervention: Influenza Vaccination
Description: The individuals will be followed to observe their immune system activation, following their vaccination with the standard influenza vaccine approved for the year by the FDA.
Study: NCT02935374

Intervention type: DRUG
Group type: OTHER
Intervention: Macrolide
Description: The children with acute otitis media with a know allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored separately
Study: NCT01949337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Enzalutamide 160 mg daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Enzalutamide 160 mg daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone
Description: abiraterone 1000 mg daily, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: prednisone 5 mg twice daily, orally
Study: NCT04569071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinovation Laser Ablation System
Description: In the present single arm study. All eligible subjects will undergo MgLiTT with the Sinovation Laser Ablation System.
Study: NCT02093351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 2 x 150mg tablets, twice daily Day 1-5, and Day 27 onwards (Cohort 1), Day 20 onwards (Cohort 2) or Day 39 onwards (Cohort 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 2 x 150mg tablets, twice daily Day 1-5, and Day 27 onwards (Cohort 1), Day 20 onwards (Cohort 2) or Day 39 onwards (Cohort 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: 2 x 150mg tablets, twice daily Day 1-5, and Day 27 onwards (Cohort 1), Day 20 onwards (Cohort 2) or Day 39 onwards (Cohort 3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 60mg Tamoxifen once daily, Day 10 - Day 13; 20mg Tamoxifen once daily, Day 14 - Day 31

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1mg Anastrozole once daily Day 10 - Day 24

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5mg Letrozole once daily Day 10 - Day 43

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling
Description: Blood sampling over 12-24 hour period for pharmacokinetic analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling
Description: Blood sampling over 12-24 hour period for pharmacokinetic analysis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling
Description: Blood sampling over 12-24 hour period for pharmacokinetic analysis
Study: NCT01454063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS302
Description: OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced salt solution (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
Study: NCT01330524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin and Triamcinolone
Description: 1.25 mg Avastin and 2mg Triamcinolone will be injected trough vitreal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2mg placebo